Lung cancer patients receiving immunochemotherapy earlier in the day had a 52% lower risk of progression in a new medical study.

A preliminary study found that people receiving immunotherapy for lung cancer or melanoma lived longer if they had received one of the mRNA vaccines

Small cell lung cancer (SCLC) is one of the most aggressive forms of lung cancer, with a five-year survival rate of only 5%. Despite this poor prognosis, SCLC is initially highly responsive to chemotherapy.

Giving immunotherapy earlier in the day can significantly extend patients' survival, compared to giving treatment later in the day, a new study of lung cancer shows.

Lung cancer battle robotic bronchoscopy improves early diagnosis and treatment access through community lung nodule programs, reducing mortality.

Wendy Brooks, a patient with extensive-stage small cell lung cancer, and her husband and care partner, Larry Brooks, sat down with CURE to talk about their journey with the disease. They reflect on the experience of diagnosis, the role of early detection, and how clinical trials have shaped Wendy’s treatment and outlook.

The pharmaceutical company said its ceralasertib combination didn’t meet the primary goal of a late-stage clinical trial for advanced lung cancer.

SCLC treatment has advanced significantly, and you will not face this journey alone. You have a dedicated medical team ready to fight alongside you.

Lung cancer screening can detect cancer early when it’s most treatable. See if you qualify for a low-dose CT scan at Fred Hutch.